Dr. Sam Denby

Managing Partner, BioFrey, United Kingdom

Dr. Denby is a Biochemical Engineer with over 20 years of experience in the bioprocess industry. He received his Engineering Doctorate in Biochemical Engineering and Bioprocess Leadership from University College London. Sam began his career in the process development group of Cambridge Antibody technology and was engaged in multiple technology development and transfer projects throughout the acquisition by AstraZeneca and merger with Medimmune. Sam subsequently joined Oxford BioMedica and was instrumental in establishing many of the process development Philosophies still in use today. Between 2010 and 2016, Sam was a technical consultant for Becton Dickinson’s Cell culture media products with responsibility for Europe, the Middle East and Africa and was involved in a number of key projects for clients with biologic products generating annual revenues of up to $16bn. Sam founded BioFrey in 2017 and has revolutionised the availability of extractables data and change notification practices around single-use systems facilitating the uptake of these systems that have proven crucial in the ongoing pandemic. Sam is currently providing CMC consultancy for a late-stage monoclonal antibody.